<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1361</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>11160228</PubmedId>
            <Abstract>The poor correlation between cellular immunity to respiratory virus infections and the numbers of memory CD8(+) T cells in the secondary lymphoid organs suggests that there may be additional reservoirs of T cell memory to this class of infection. Here we identify a substantial population of Ag-specific T cells in the lung that persist for several months after recovery from an influenza or Sendai virus infection. These cells are present in high numbers in both the airways and lung parenchyma and can be distinguished from memory cell populations in the spleen and peripheral lymph nodes in terms of the relative frequencies among CD8(+) T cells, activation status, and kinetics of persistence. In addition, these cells are functional in terms of their ability to proliferate, express cytolytic activity, and secrete cytokines, although they do not express constitutive cytolytic activity. Adoptive transfer experiments demonstrated that the long-term establishment of activated T cells in the lung did not require infection in the lung by a pathogen carrying the inducing Ag. The kinetics of persistence of Ag-specific CD8(+) T cells in the lung suggests that they play a key role in protective cellular immunity to respiratory virus infections.</Abstract>
            <ArticleYear>2001</ArticleYear>
            <ArticlePages>1813-22</ArticlePages>
            <ArticleTitle>Activated antigen-specific CD8+ T cells persist in the lungs following recovery from respiratory virus infections.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Hogan</LastName>
                    <ForeName>R J</ForeName>
                </Author>
                <Author>
                    <LastName>Usherwood</LastName>
                    <ForeName>E J</ForeName>
                </Author>
                <Author>
                    <LastName>Zhong</LastName>
                    <ForeName>W</ForeName>
                </Author>
                <Author>
                    <LastName>Roberts</LastName>
                    <ForeName>A A</ForeName>
                </Author>
                <Author>
                    <LastName>Dutton</LastName>
                    <ForeName>R W</ForeName>
                </Author>
                <Author>
                    <LastName>Harmsen</LastName>
                    <ForeName>A G</ForeName>
                </Author>
                <Author>
                    <LastName>Woodland</LastName>
                    <ForeName>D L</ForeName>
                </Author>
            </Authors>
            <Affiliations>Trudeau Institute, Saranac Lake, NY 12983, USA.</Affiliations>
            <ArticleChemicalList>Epitopes, T-Lymphocyte;Nucleocapsid Proteins;Nucleoproteins;Viral Core Proteins</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; CD8-Positive T-Lymphocytes(immunology; metabolism; virology); Cells, Cultured; Convalescence; Cytotoxicity, Immunologic; Epitopes, T-Lymphocyte(immunology); Female; Immunologic Memory; Immunophenotyping; Influenza A virus(immunology); Lung(immunology; virology); Lymphocyte Activation; Lymphocyte Count; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nucleocapsid Proteins; Nucleoproteins; Orthomyxoviridae Infections(immunology); Respiratory Tract Infections(immunology; virology); Respirovirus(immunology); Respirovirus Infections(immunology); T-Lymphocyte Subsets(immunology; metabolism; virology); Viral Core Proteins(immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>166</Volume>
                <Issue>3</Issue>
                <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
                <Issn>0022-1767</Issn>
                <MedlineTa>J Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>NP366-374</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ASNENMETM</LinearSequence>
                        <StartingPosition>366</StartingPosition>
                        <EndingPosition>374</EndingPosition>
                        <SourceMolecule>
                            <IedbAccession>SRC124</IedbAccession>
                        </SourceMolecule>
                        <SourceOrganismId>211044</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Authors communication</LocationOfData>
                <EpitopeId>4602</EpitopeId>
                <ReferenceStartingPosition>366</ReferenceStartingPosition>
                <ReferenceEndingPosition>374</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Epitopic sequence is conserved in the Flu/HK-x31 strain also used in this work.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Fig 6</LocationOfData>
                        <TCellId>21758</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>1 dose of 300 EID50</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>T cell</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>ASNENMETM</LinearSequence>
                                            <StartingPosition>366</StartingPosition>
                                            <EndingPosition>374</EndingPosition>
                                            <SourceMolecule>
                                                <IedbAccession>SRC124</IedbAccession>
                                            </SourceMolecule>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Cells were recovered form lungs and lymphoid tissue 31 days post infection.  Ag-specific cells form different tissues were stimulated for 4 days in the presence of peptide, IL-2 and Î³-irradiated splenocytes. Proliferating cells were studied for the lytic activity.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Bronchial Aveolar Lavage (BAL)</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>L cells-Fibroblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP366-374</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ASNENMETM</LinearSequence>
                                        <StartingPosition>366</StartingPosition>
                                        <EndingPosition>374</EndingPosition>
                                        <SourceMolecule>
                                            <IedbAccession>SRC124</IedbAccession>
                                        </SourceMolecule>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The memory population of CD8+ cells remaining in the lungs 31 days after infection is shown to be able to proliferate in vitro in response to peptide stimulation (Fig 5), and to acquire specific cytolytic activity against peptide pulsed L-Db target cells. Thus, the cells that reside in the lungs long after infection is resolved are not constitutively cytolytic but can be induced to proliferate and acquire lytic capacity.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <TCellId>21739</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>1 dose of 300 EID50 as a primary infection, 3000 EID50 of PR8/34 strain as a secondary infection.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The secondary immunization was performed 88 days after the primary infection.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Bronchial Aveolar Lavage (BAL)</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP366-374</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ASNENMETM</LinearSequence>
                                        <StartingPosition>366</StartingPosition>
                                        <EndingPosition>374</EndingPosition>
                                        <SourceMolecule>
                                            <IedbAccession>SRC124</IedbAccession>
                                        </SourceMolecule>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>A high (~10^5 cells/mouse) and constant number of epitope specific CD8+ splenocytes are detected in the spleen of HKx31 infected mice even 3 months after infection. By contrast, lung airways have a slowly declining population of these cells (BAL), declining from ~2x10^3 (~13% of CD8+ BAL) to ~2x10^2 at 3 months after infection. Higher numbers of this cells, but similarly declining, are observed in the lung tissue. The phenotypic profile of the cells from lung and spleen shows that the former express a higher level of activation markers (CD69, CD25, CD43), while CD62L expression was lower than in spleen at all time points after infection. This population of cells are shown by adoptive transfer studies (Fig 7) to be found even in the absence of a primary infection of the lung or of persisting antigen, suggesting the lung, and possibly other mucosal sites, may act to selectively recruit activated memory cells from the circulating pool. Upon secondary infection with FluA/PR8, there is a considerable expansion of epitope specific cells in all tissues at 32 days post infection. .</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>NP324-332</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>FAPGNYPAL</LinearSequence>
                        <StartingPosition>324</StartingPosition>
                        <EndingPosition>332</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P04857.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11194</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Authors communication</LocationOfData>
                <EpitopeId>15248</EpitopeId>
                <ReferenceStartingPosition>324</ReferenceStartingPosition>
                <ReferenceEndingPosition>332</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Epitopic sequence is conserved in other strains.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <TCellId>21759</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11194</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>1 dose of 500 EID50</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Bronchial Aveolar Lavage (BAL)</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP324-332</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FAPGNYPAL</LinearSequence>
                                        <StartingPosition>324</StartingPosition>
                                        <EndingPosition>332</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P04857.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11194</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>A high (~10^5 cells/mouse) and constant number of epitope specific CD8+ splenocytes are detected in the spleen of Sendai infected mice even 3 months after infection. By contrast, lung airways have a slowly declining population of these cells (BAL), declining from10^4 (~60% of CD8+ BAL) to less than 1000 cells (~16%) one year afer infection. Higher numbers of this cells, but similarly declining, are observed in the lung tissue. The phenotypic profile of the cells from lung and spleen shows that the former express a higher level of activation markers (CD69, CD25, CD43), while CD62L expression was lower than in spleen at all time points after infection.This population of cells are shown by adoptive transfer studies (Fig 7) to be found even in the absence of a primary infection of the lung or of persisting antigen, suggesting the lung, and possibly other mucosal sites, may act to selectively recruit activated memory cells from the circulating pool.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

